MCL1 and cancer: Additionally, PROTAC2 potently sensitizes the pancreatic cancer cell line MiaPaCa2 to the BCL2 inhibitor, venetoclax.110 Resistance to BCL2 has been attributed to the compensatory activity of MCL-1; therefore, MCL-1 inactivation sensitizes cancer cells to BCL2 inhibitors.